Orexigen Therapeutics, Inc. has entered into a commercial supply agreement with Sanofi for the manufacture of Contrave (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America. Sanofi will manufacture Contrave tablets at one of several facilities in France.
 
“We are pleased to engage a manufacturer with Sanofi’s scale and expertise,” said Michael Narachi, chief executive officer of Orexigen. “This agreement expands and diversifies our existing commercial supply network and will help ensure we will be ready to supply Contrave globally if approved.”